These findings are in contrast to what is commonly seen with cytotoxic chemotherapies [14]; this is especially relevant as CDK4/6 inhibitors are currently being evaluated in the early breast cancer setting [15]. The gene discussed is CDK4; the disease is breast carcinoma.